Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials according to brca mutational status

It is by now widely recognized that ovarian cancer (OC) harbours a remarkable degree of genomic disarray and instability and presents with a wide range of mutations [1,2]. Indeed, around 50% of all high-grade serous ovarian tumours are estimated to have a deficiency in the homologous recombination (HR) DNA repair mechanism, with about 15% of carcinomas harbouring a germline and 6% a somatic Breast Related Cancer Antigens (BRCA) 1-2 mutation. These mutations confer to the cell a disability to repair DNA through the HR pathway, leading to a condition defined as homologous recombination deficiency (HRD) [1,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research